Sign In
Buy BIO
$301.70
-0.200 (-0.0662%)
At Close: Jul 21, 2026
Bio-Rad Laboratories (BIO) to Post Q3 Earnings: What Awaits?
02:17pm, Friday, 20'th Oct 2023
Bio-Rad (BIO) Life Science segment will likely have witnessed growth in Q3, driven by Droplet Digital PCR and qPCR products.
Bio-Rad Laboratories (BIO) Earnings Expected to Grow: Should You Buy?
11:18am, Thursday, 19'th Oct 2023
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 19th
06:46am, Tuesday, 19'th Sep 2023
BIO, LPG and COLB have been added to the Zacks Rank #5 (Strong Sell) List on September 19, 2023.
3 Beaten-Down Biotech Stocks Bound for a Bounce Back
07:38am, Saturday, 02'nd Sep 2023
Biotech stocks soared high during the COVID-19 pandemic, as they were our only hope for new drugs and vaccines to fight the virus. However, the biotech sector received little thanks from the market wh
New Strong Sell Stocks for August 18th
09:34am, Friday, 18'th Aug 2023
BIO, REFI and GPK have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2023.
New Strong Sell Stocks for August 9th
08:27am, Wednesday, 09'th Aug 2023
BWA, ARR and BIO have been added to the Zacks Rank #5 (Strong Sell) List on August 9, 2023.
Bio-Rad (BIO) Beats on Q2 Earnings Estimates, Cuts 2023 View
01:32pm, Friday, 04'th Aug 2023
Growth across the Life Science portfolio and strong double-digit growth for ddPCR drive Bio-Rad (BIO) Q2 performance.
Bio-Rad Laboratories, Inc. (BIO) Q2 2023 Earnings Call Transcript
11:33pm, Thursday, 03'rd Aug 2023
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q2 2023 Earnings Conference Call August 3, 2023 5:00 PM ET Company Participants Edward Chung - Head, Investor Relations Norman Schwartz - Chief Executive Officer
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
10:08am, Tuesday, 25'th Jul 2023
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023
04:30pm, Monday, 10'th Jul 2023
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the
Bio-Rad (BIO) Faces Macroeconomic Headwinds, Rising Expenses
11:20am, Thursday, 01'st Jun 2023
Bio-Rad's (BIO) process chromatography business witnesses a slowdown in the quarter due to tough comparisons and some softness in the bioprocessing market.
Bio-Rad And Its Real Value
06:18am, Tuesday, 16'th May 2023
Bio-Rad previously experienced a significant jump in sales due to Covid-19 testing. However, with Covid-related sales falling off, the overall revenue has also been reduced in 2022.
Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down
09:09am, Friday, 05'th May 2023
Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.
Bio-Rad Laboratories, Inc. (BIO) Q1 2023 Earnings Call Transcript
10:48pm, Thursday, 04'th May 2023
Bio-Rad Laboratories, Inc. (NYSE:BIO ) Q1 2023 Results Conference Call May 4, 2023 5:00 PM ET Company Participants Ed Chung - Vice President, Investor Relations Norman Schwartz - Chief Executive Offic
Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?
11:25am, Monday, 01'st May 2023
Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.
